Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997532 | 1.00 | KMT2A (0.54) | KMT2ATSHRHTR2AHTR7EPHX2 | |
| SCHEMBL1060544 | 1.00 | KMT2A (0.54) | KMT2ATSHRHTR2AHTR7EPHX2 | |
| SCHEMBL1060542 | 1.00 | KMT2A (0.54) | KMT2ATSHRHTR2AHTR7EPHX2 | |
| SCHEMBL12931837 | 0.88 | EPHX2 (0.49) | KMT2ATSHRHTR2AHTR7EPHX2 | |
| SCHEMBL18809479 | 0.87 | L3MBTL1 (0.52) | KMT2ATSHRHTR2AHTR7EPHX2 | |
| SCHEMBL6154422 | 0.79 | TRPV4 (0.46) | KMT2ATSHRL3MBTL1MAOA | |
| SCHEMBL14658348 | 0.78 | L3MBTL1 (0.54) | KMT2ATSHRL3MBTL1SMN1; SMN2MAOA | |
| SCHEMBL14658349 | 0.78 | L3MBTL1 (0.54) | KMT2ATSHRL3MBTL1SMN1; SMN2MAOA | |
| SCHEMBL31295019 | 0.78 | L3MBTL1 (0.54) | KMT2ATSHRL3MBTL1SMN1; SMN2MAOA | |
| SCHEMBL2665681 | 0.78 | L3MBTL1 (0.54) | KMT2ATSHRL3MBTL1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1814875-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | The Regents of the University of California (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-30 | — | — | US | disclosed |
| WO-2006045119-A9 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006045119-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | KMT2A 2899/4885TSHR 3705/4885HTR2A 2231/4885 |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | EPHX1, EPHX2, NCEH1 | KMT2A 2899/4885TSHR 3705/4885HTR2A 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.